Loading…
CytomX Therapeutics, Inc. is projected to rise to $4.15 by 2027, a +10% move from its current price of $3.76. CTMX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.65 | $3.76 | $3.88 | +0.02% |
| Jul 15 | $3.60 | $3.76 | $3.93 | +0.05% |
| Jul 16 | $3.57 | $3.76 | $3.97 | +0.07% |
| Jul 17 | $3.54 | $3.76 | $4.01 | +0.10% |
| Jul 18 | $3.51 | $3.76 | $4.04 | +0.12% |
| Jul 19 | $3.49 | $3.77 | $4.06 | +0.15% |
| Jul 20 | $3.47 | $3.77 | $4.09 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.47 | $3.77 | $4.09 | +0.17% |
| Week 2 | $3.36 | $3.77 | $4.24 | +0.34% |
| Week 3 | $3.28 | $3.78 | $4.36 | +0.51% |
| Week 4 | $3.21 | $3.79 | $4.46 | +0.68% |
| Week 5 | $3.15 | $3.79 | $4.56 | +0.85% |
| Week 6 | $3.11 | $3.80 | $4.65 | +1.02% |
| Week 7 | $3.06 | $3.80 | $4.73 | +1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
The company was founded in 2008 and is based in South San Francisco, California.
CTMX is the CytomX Therapeutics equity, trading with a current price of $3.74 and a market capitalization of $814.21M. It holds a rank of 2578 among listed equities. The long-run price outlook from the provided forward forecast shows a path of growth, with 2026 expecting an avg near $3.74 and rising toward the 2030–2050 milestones, including a 2050 average around $16.09 and potential upside to the mid-to-upper range in later years.
The forecast also displays a clear long-term bullish tilt beginning around 2031 onward, aligning with the company’s multi-program pipeline and ongoing collaborations.
A major floor 33.6% below — a decisive break under it would weaken the trend.
The nearest floor, 22.6% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 79.5% above — clearing it would confirm fresh momentum.
Key CTMX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTMX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.84 | Sell | $3.81 | Sell |
| MA 10 | $3.75 | Buy | $3.71 | Buy |
| MA 20 | $3.41 | Buy | $3.57 | Buy |
| MA 50 | $3.56 | Buy | $3.66 | Buy |
| MA 100 | $4.18 | Sell | $3.89 | Sell |
| MA 200 | $4.16 | Sell | $3.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.80 | Neutral |
| Stoch RSI (14) | 70.18 | Neutral |
| CCI (20) | 68.36 | Neutral |
| Williams %R (14) | -21.31 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 19.37 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 78.69 | Neutral |
| TRIX (15) | 0.14 | Buy |
| Awesome (5,34) | 0.45 | Buy |
| Ultimate (7,14,28) | 57.85 | Neutral |
| Momentum (10) | 0.49 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 3.90 | Sell |
| ADX (14) | 26.32 | Buy |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is bullish overall, with RSI(14) at 60. The near-term moving averages show a mild bullish crossover context, with the 50-day simple moving average at $3.68 guiding the near-term trend while the 200-day simple moving average sits at $4.09. A defined support level is at $2.91 and a resistance at $3.81, providing a framework for potential pullbacks or breakouts.
The thirty-day price range spans from a low of $3.01 to a high of $4.65, reflecting a still-narrow window around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.91 | $3.76 | $5.11 | 0% | Neutral | |
| $3.26 | $4.15 | $5.62 | +10% | Neutral | |
| $3.18 | $4.17 | $5.88 | +11% | Neutral | |
| $3.23 | $4.36 | $6.35 | +16% | Neutral | |
| $3.17 | $4.38 | $6.55 | +17% | Neutral | |
| $3.44 | $4.87 | $7.45 | +29% | Bullish | |
| $3.88 | $5.59 | $8.74 | +49% | Bullish | |
| $4.26 | $6.26 | $9.97 | +66% | Bullish | |
| $4.73 | $7.08 | $11.48 | +88% | Bullish | |
| $4.41 | $6.72 | $11.07 | +79% | Bullish | |
| $6.21 | $10.24 | $18.06 | +172% | Bullish | |
| $8.62 | $16.36 | $31.81 | +335% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.91 | $3.76 | $4.60 | +0.00% |
| August 2026 | $3.23 | $3.83 | $4.67 | +1.91% |
| September 2026 | $3.22 | $3.84 | $4.75 | +0.32% |
| October 2026 | $3.35 | $4.02 | $5.02 | +4.70% |
| November 2026 | $3.40 | $4.11 | $5.18 | +2.23% |
| December 2026 | $3.31 | $4.03 | $5.11 | -2.05% |
Click any year to see its month-by-month CTMX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CTMX could reach as high as $5.11, with a base case around $3.76 and support toward $2.91 — roughly 0% from $3.76. A consolidation phase looks the most probable path here.
Expect CTMX to range from $3.26 to $5.62 through 2027. The $4.15 average target implies a +10% move from current prices. That is up +10% on the projected 2026 average. Price action looks broadly range-bound.
The CTMX price prediction for 2028 points to an average of $4.17 (low $3.18, high $5.88) — a potential gain of +11% on today's $3.76. A consolidation phase looks the most probable path here.
In 2029, CTMX is projected to trade between $3.23 and $6.35, averaging $4.36 — a potential gain of +16% from today's $3.76. That is up +5% on the projected 2028 average. Price action looks broadly range-bound.
CytomX Therapeutics, Inc.'s 2030 outlook centres on $4.38, within a $3.17 to $6.55 range. That is up 0% on the projected 2029 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, CTMX could reach as high as $7.45, with a base case around $4.87 and support toward $3.44 — roughly +29% from $3.76. Momentum favours further upside here.
Expect CTMX to range from $3.88 to $8.74 through 2032. The $5.59 average target implies a +49% move from current prices. That is up +15% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The CTMX price prediction for 2033 points to an average of $6.26 (low $4.26, high $9.97) — a potential gain of +66% on today's $3.76. Momentum favours further upside here.
In 2034, CTMX is projected to trade between $4.73 and $11.48, averaging $7.08 — a potential gain of +88% from today's $3.76. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
CytomX Therapeutics, Inc.'s 2035 outlook centres on $6.72, within a $4.41 to $11.07 range. That is -5% versus the projected 2034 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2040, CTMX could reach as high as $18.06, with a base case around $10.24 and support toward $6.21 — roughly +172% from $3.76. Buyers look set to stay in control over this stretch.
Expect CTMX to range from $8.62 to $31.81 through 2050. The $16.36 average target implies a +335% move from current prices. That is up +60% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CTMX today (≈ 265.957447 CTMX) could be worth
$4,351.84
+$3,351.84 (+335%) by 2050 · US Dollar
Based on the average projected CTMX price of $16.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTMXwould be worth at today's price.
$1,000 invested in CTMX on Jul 10, 2025 (≈ 384.615399 CTMX) would be worth
$1,446.15
+$446.15 (+44.6%) today · 1.45× · US Dollar
Based on a CTMX entry price of $2.6 vs. today's $3.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.82 | $984.29 | -1.6% |
| 1 month ago | $2.91 | $1,292.1 | +29.2% |
| 3 months ago | $4.39 | $856.49 | -14.4% |
| 6 months ago | $4.34 | $866.36 | -13.4% |
| 1 year ago | $2.6 | $1,446.15 | +44.6% |
| All time (5.0y) ago | $5.8 | $648.28 | -35.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTMX forecast.
Our base-case forecast reaches $7.50 around 2040.
Implied market cap at $7.50: $1.63B
The multi-year forecast shows a progressive rise in average price and a strong jump in upside potential over time. For 2030, the average is $4.40 with a min of $3.14 and a max of $6.67, and a predicted ROI of 17.6. By 2040, the average climbs to $10.16 with a min of $5.99 and a max of $18.29, delivering a forecasted ROI of 171.6.
In 2050, the average is projected at $16.09 with a min of $8.14 and a max of $32.05, yielding an estimated ROI of 330.2. The sentiment profile shifts to BULLISH from 2031 onward, reflecting stronger longer-term conviction.
Tap a question to reveal the answer.
2030 forecast shows an average price of $4.40, a min of $3.14, and a max of $6.67 with an ROI of 17.6 and NEUTRAL sentiment.
The 2026 forecast assigns an average price of $3.74 with NEUTRAL sentiment, while longer-term outlook from 2031 onward is BULLISH.
2035 forecast lists a min of $4.26, an average of $6.61, and a max of $11.10 with an ROI of 76.9 and BULLISH sentiment, indicating potential to exceed $10 in the outlook.
The 2050 forecast shows an average price of $16.09 with a max of $32.05 and a min of $8.14, delivering an ROI of 330.2 and a BULLISH sentiment.
The current price is $3.74 and the market cap is $814.21M.
CytomX Therapeutics, Inc. Community Discussion
0Share your CytomX Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.